REPAY Stock Rises After Visa Platform Connect Collaboration 
Unitree Robotics Shares Soar Over 600% in Shanghai Market Debut 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Toyota, Honda Shares Rise on Possible U.S.-Canada Auto Tariff Cut 
Alibaba Shares Fall as AI Spending Hits Profit 
Welspun Corp Shares Hit Record High on $1.8 Billion U.S. Order 
SEC Sues Former Tricolor Executives Over $1.9 Billion Investor Fraud Scheme 
Coty Revenue Beats Estimates as Beauty Demand Holds Firm 
OpenAI Tightens AI Safety Monitoring After Security Incidents 
Unifor Reaches Tentative GM Deal for 4,600 Ontario Workers 
Nvidia AI Server Prices Set to Rise as Memory Costs Surge 
Moody’s Affirms NVIDIA Aa1 Rating as AI Data Center Guarantees Reach $105 Billion 
Nordson Stock Rises as Q3 Earnings Beat Estimates, Outlook Raised 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
Anthropic Eyes $10B-Plus Credit Line Ahead of Potential IPO 
Goldman Sachs Names 9 Top Japanese Semiconductor and Electronics Stocks 
Add as a preferred source on Google
BOTHELL, Wash., May 07, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast a business overview and update by Paul B. Cleveland, Interim President and Chief Executive Officer, at the 2018 Bank of America Merrill Lynch Health Care Conference at 1:15 p.m. PT on Tuesday, May 15, 2018 in Las Vegas, NV.
A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on transforming the migraine treatment paradigm through the discovery, development and commercialization of novel therapeutic antibodies. Alder’s lead product candidate, eptinezumab, is a monoclonal antibody (mAb) that inhibits calcitonin gene-related peptide (CGRP) and is currently in late-stage clinical development for the prevention of migraine. Unlike other CGRP inhibitors, eptinezumab was specifically designed as an infusion therapy to address significant patient need. Alder is also developing ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) for migraine prevention. For more information, please visit www.alderbio.com.
Investor Relations Contacts:
Ashwin Agarwal
Vice President, Corporate Strategy
Alder Biopharmaceuticals, Inc.
425-408-8567
[email protected]
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]
Media Contact:
Andy Brimmer / Aura Reinhard / Trevor Gibbons
Joele Frank, Wilkinson Brimmer Katcher
212-355-4449
